-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo

Benzinga·07/09/2026 06:34:55
Listen to the news
  • Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy 
  • Favorable safety profile consistent with previous results